{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:02Z","timestamp":1792001522278,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ygyno.2021.10.072","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T08:22:48Z","timestamp":1635150168000},"page":"221-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis"],"prefix":"10.1016","volume":"164","author":[{"given":"Vera M.","family":"Witjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majke H.D.","family":"van Bommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn J.L.","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet R.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.E.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet G.E.M.","family":"Ausems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalling","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoline","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"issue":"44","key":"10.1016\/j.ygyno.2021.10.072_bb0010","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.10.072_bb0020","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3390\/cancers12103046","article-title":"Rare germline genetic variants and the risks of epithelial ovarian cancer","volume":"12","author":"Pavanello","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes - providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnci\/djz080","article-title":"Universal tumor DNA BRCA1\/2 testing of ovarian Cancer: prescreening PARPi treatment and genetic predisposition","volume":"112","author":"Vos","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.10.072_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2016.11.028","article-title":"Linking uterine serous carcinoma to BRCA1\/2-associated cancer syndrome: a meta-analysis and case report","volume":"72","author":"de Jonge","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2021.10.072_bb0040","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.10.072_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","article-title":"Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review","volume":"61","author":"Arts-de Jong","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2021.10.072_bb0050","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian Cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","article-title":"Selecting patients with ovarian Cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review","volume":"33","author":"Eccles","year":"2016","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0065","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"issue":"suppl_8","key":"10.1016\/j.ygyno.2021.10.072_bb0070","doi-asserted-by":"crossref","first-page":"viii8","DOI":"10.1093\/annonc\/mdx445","article-title":"The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications","volume":"28","author":"Duska","year":"2017","journal-title":"Ann. Oncol: Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","article-title":"Histotype classification of ovarian carcinoma: a comparison of approaches","volume":"151","author":"Peres","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0080","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","article-title":"The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications","volume":"293","author":"Meinhold-Heerlein","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"issue":"7","key":"10.1016\/j.ygyno.2021.10.072_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.ygyno.2021.10.072_bb0090","first-page":"147","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"JBI Evid. Implement."},{"issue":"29","key":"10.1016\/j.ygyno.2021.10.072_bb0095","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2021.10.072_bb0100","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res. Synth. Methods"},{"issue":"7414","key":"10.1016\/j.ygyno.2021.10.072_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"10","key":"10.1016\/j.ygyno.2021.10.072_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ygyno.2021.10.072_bb0120","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/jmedgenet-2018-105930","article-title":"Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)","volume":"56","author":"Hauke","year":"2019","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.ygyno.2021.10.072_bb0125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/a-1222-0042","article-title":"Prevalence of BRCA1 and BRCA2 mutations in patients with primary ovarian cancer - does the German checklist for detecting the risk of hereditary breast and ovarian cancer adequately depict the need for consultation?","volume":"80","author":"Ataseven","year":"2020","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"11","key":"10.1016\/j.ygyno.2021.10.072_bb0130","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/jog.14090","article-title":"BRCA mutation frequency and clinical features of ovarian cancer patients: a report from a Chinese study group","volume":"45","author":"Bu","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"8","key":"10.1016\/j.ygyno.2021.10.072_bb0135","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/IGC.0000000000000529","article-title":"Germline mutations of <em>BRCA1<\/em> and <em>BRCA2<\/em> in Korean ovarian cancer patients: finding founder mutations","volume":"25","author":"Choi","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.10.072_bb0140","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2021.10.072_bb0145","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41431-020-0692-y","article-title":"Mainstreaming germline BRCA1\/2 testing in non-mucinous epithelial ovarian cancer in the north west of England","volume":"28","author":"Flaum","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0150","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci. Rep."},{"issue":"68","key":"10.1016\/j.ygyno.2021.10.072_bb0155","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","article-title":"Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","volume":"8","author":"Hirasawa","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0160","first-page":"1229","article-title":"Germline and somatic BRCA1\/2 gene mutational status and clinical outcomes in epithelial peritoneal, ovarian, and fallopian tube cancer: over a decade of experience in a single institution in Korea","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5114\/pjp.2019.82905","article-title":"Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples \u2013 single institution study","volume":"70","author":"Kowalik","year":"2019","journal-title":"Pol. J. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.10.072_bb0170","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.31557\/APJCP.2020.21.8.2381","article-title":"Prevalence of tissue BRCA gene mutation in ovarian, fallopian tube, and primary peritoneal cancers: a multi-institutional study","volume":"21","author":"Lertkhachonsuk","year":"2020","journal-title":"Asian Pacif. J. Cancer Prevent.: APJCP"},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/cancers12040956","article-title":"Multigene panel germline testing of 1333 Czech patients with ovarian cancer","volume":"12","author":"Lhotova","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13048-019-0560-y","article-title":"Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study","volume":"12","author":"Li","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"11","key":"10.1016\/j.ygyno.2021.10.072_bb0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5306\/wjco.v10.i11.358","article-title":"Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer","volume":"10","author":"Manchana","year":"2019","journal-title":"World J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.10.072_bb0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/jmedgenet-2018-105792","article-title":"Prevalence of germline pathogenic BRCA1\/2 variants in sequential epithelial ovarian cancer cases","volume":"56","author":"Morgan","year":"2019","journal-title":"J. Med. Genet."},{"issue":"1318","key":"10.1016\/j.ygyno.2021.10.072_bb0195","article-title":"Tumor testing for somatic and germline BRCA1\/BRCA2 variants in ovarian cancer patients in the context of strong founder effects","volume":"10","author":"Peixoto","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.10.072_bb0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jmedgenet-2016-103902","article-title":"New paradigms for BRCA1\/BRCA2 testing in women with ovarian cancer: results of the genetic testing in epithelial ovarian Cancer (GTEOC) study","volume":"53","author":"Plaskocinska","year":"2016","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2021.10.072_bb0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jmedgenet-2017-105140","article-title":"Mainstreamed genetic testing for women with ovarian cancer: first-year experience","volume":"56","author":"Rahman","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2021.10.072_bb0210","article-title":"Implementing NGS-based <em>BRCA<\/em> tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations","author":"Rivera","year":"2020","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0215","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/s41598-020-60149-5","article-title":"Oncologist-led BRCA \u2018mainstreaming\u2019 in the ovarian cancer clinic: a study of 255 patients and its impact on their management","volume":"10","author":"Rumford","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ygyno.2021.10.072_bb0220","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/1471-0528.15171","article-title":"Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience","volume":"125","author":"Rust","year":"2018","journal-title":"Bjog"},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0225","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.29707","article-title":"BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.10.072_bb0230","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5468\/ogs.2019.62.6.411","article-title":"Prevalence and oncologic outcomes of BRCA1\/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea","volume":"62","author":"Seo","year":"2019","journal-title":"Obstet. Gynecol. Sci."},{"issue":"9","key":"10.1016\/j.ygyno.2021.10.072_bb0235","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.30633","article-title":"BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer","volume":"140","author":"Shi","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0240","doi-asserted-by":"crossref","first-page":"17808","DOI":"10.1038\/s41598-019-54116-y","article-title":"Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients","volume":"9","author":"Sugino","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ygyno.2021.10.072_bb0245","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","article-title":"The first Nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian Cancer patients","volume":"27","author":"Wu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2021.10.072_bb0250","first-page":"A516","article-title":"EP973 \u2018tumour first\u2019: an institutional experience of reflex tumour BRCA testing in ovarian epithelial carcinomas","volume":"29","author":"Santandrea","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2021.10.072_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy","volume":"120","author":"Schrader","year":"2012","journal-title":"Obstet. Gynecol."},{"issue":"23","key":"10.1016\/j.ygyno.2021.10.072_bb0260","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0265","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0270","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.path.2019.01.009","article-title":"Pathology of endometrioid and clear cell carcinoma of the ovary","volume":"12","author":"Fadare","year":"2019","journal-title":"Surg. Pathol. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.072_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ajo.13105","article-title":"Low-grade serous ovarian carcinoma: a comprehensive literature review","volume":"60","author":"Goulding","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0280","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41379-019-0401-y","article-title":"Two types of primary mucinous ovarian tumors can be distinguished based on their origin","volume":"33","author":"Simons","year":"2020","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.10.072_bb0285","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0290","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes \u2014 providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.10.072_bb0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/qjmed\/hcv137","article-title":"Lynch syndrome in the 21st century: clinical perspectives","volume":"109","author":"Tiwari","year":"2015","journal-title":"QJM: Int. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2021.10.072_bb0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1470-2045(09)70041-5","article-title":"Management of extracolonic tumours in patients with Lynch syndrome","volume":"10","author":"Koornstra","year":"2009","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2021.10.072_bb0305","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial Cancer molecular risk stratification is equally prognostic for Endometrioid ovarian carcinoma","volume":"26","author":"Kr\u00e4mer","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.10.072_bb0310","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2018.03.060","article-title":"Characteristics of Lynch syndrome associated ovarian cancer","volume":"150","author":"Woolderink","year":"2018","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582101516X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582101516X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:21Z","timestamp":1758772761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582101516X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S009082582101516X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.072","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}